Brainsway (BWAY)
(Delayed Data from NSDQ)
$8.02 USD
+0.11 (1.39%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.02 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.02 USD
+0.11 (1.39%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.02 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth A Momentum B VGM
Zacks News
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and ChromaDex (CDXC) have performed compared to their sector so far this year.
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Why Brainsway (BWAY) Might be Well Poised for a Surge
by Zacks Equity Research
Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Brainsway (BWAY) Could Surge 72.29%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Brainsway (BWAY) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strength Seen in Brainsway (BWAY): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold
by Zacks Equity Research
BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
by Zacks Equity Research
BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.
What's in Store for Cooper Companies (COO) in Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 120.45%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 120.5% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)
by Zacks Equity Research
Brainsway (BWAY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for March 11th
by Zacks Equity Research
BWAY, WILYY and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 11, 2024.
New Strong Buy Stocks for March 11th
by Zacks Equity Research
BWAY, WILLY, IDCC, BRKL and SBSI have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2024.
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
by Zacks Equity Research
Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.
Zacks.com featured highlights VirTra, Universal Stainless & Alloy, Carrols Restaurant, BrainsWay and Virco
by Zacks Equity Research
VirTra, Universal Stainless & Alloy, Carrols Restaurant, BrainsWay and Virco have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength in a Volatile Market
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are VTSI, USAP, TAST, BWAY, VIRC.
3 Top-Ranked Small-Caps Delivering Large Gains
by Derek Lewis
Small-caps have found plenty of buyers over the last few months, undoubtedly a welcomed development as investors look to find strength outside of large-caps.
Recent Price Trend in Brainsway Ltd. Sponsored ADR (BWAY) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway Ltd. Sponsored ADR (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Best Momentum Stocks to Buy for January 2nd
by Zacks Equity Research
BWAY, RYAAY and EQX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 2, 2024.
New Strong Buy Stocks for January 2nd
by Zacks Equity Research
GPRE, FFIC, NGD, BWAY and EQX have been added to the Zacks Rank #1 (Strong Buy) List on January 2, 2024.
Does Brainsway Ltd. Sponsored ADR (BWAY) Have the Potential to Rally 48.15% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 48.2% upside potential for Brainsway Ltd. Sponsored ADR (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
by Zacks Equity Research
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Predict a 68.72% Upside in Brainsway Ltd. Sponsored ADR (BWAY): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Brainsway Ltd. Sponsored ADR (BWAY) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.